Darunavir + ritonavir
Darunavir + ritonavir has been studied in 3 papers since 2016: 1 trial in people, 2 in cells. The newest paper, Dec 20, 2022: “Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal”.
See all 7 papers on darunavir + ritonavir
At a glance
The findings reach cells, none yet in people. 1 lab in 1 country.
Cells: a single group. Worms or flies, mice and humans: nothing yet.
- 1 lab in 1 country
- Human trial1
- Cells2
What did studies of darunavir + ritonavir find?
1Studies of darunavir + ritonavir measured one outcome, cellular senescence.
Cellular senescence
upin human cells1
1 study
Cellular senescence
upin human cells1
Darunavir + ritonavir increases cellular senescence in endothelial cells from adult donors.
“In endothelial cells from adult donors, we confirmed that ATV/r and DRV/r adversely affected all assessed endothelial functions and enhanced senescence”
Cellsin endothelial cells from adult donorscoronary artery15 days
Antiviral therapy
Latest
1 paper in 12 monthsAntiviral Therapy
Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence
Experiments in human cellsInterventions
The Journal of Infectious Diseases
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s
Randomized trial in 328 peopleBlood and immune system
The Lancet HIV
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial
Randomized trial in 168 peopleGrimAge
HIV Medicine
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial
Cross-sectional study of 201 peopleTelomere length